Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate (original) (raw)

• Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L . Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003; 4: 75–85.
  Article PubMed Google Scholar
• von Bubnoff N, Peschel C, Duyster J . Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia 2003; 17: 829–838.
  Article CAS PubMed Google Scholar
• Luzzatto L, Frassoni F, Melo JV . Imatinib: can one outwit chronic myeloid leukemia? Haematologica 2002; 87: 898–901.
  PubMed Google Scholar
• Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96: 1070–1079.
  CAS PubMed Google Scholar
• le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000; 95: 1758–1766.
  CAS PubMed Google Scholar
• Weisberg E, Griffin JD . Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000; 95: 3498–3505.
  CAS PubMed Google Scholar
• Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Faderl S et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003; 101: 473–475.
  Article CAS PubMed Google Scholar
• Corbin AS, Rosee PL, Stoffregen EP, Druker BJ, Deininger MW . Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003; 101: 4611–4614.
  Article CAS PubMed Google Scholar
• Tipping AJ, Mahon FX, Lagarde V, Goldman JM, Melo JV . Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells. Blood 2001; 98: 3864–3867.
  Article CAS PubMed Google Scholar
• Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–880.
  Article CAS PubMed Google Scholar
• Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190–2196.
  Article CAS PubMed Google Scholar
• Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690–698.
  Article CAS PubMed Google Scholar
• Tipping AJ, Deininger MW, Goldman JM, Melo JV . Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Exp Hematol 2003; 31: 1073–1080.
  Article CAS PubMed Google Scholar
• Tipping AJ, Melo JV . Imatinib mesylate in combination with other chemotherapeutic drugs: in vitro studies. Semin Hematol 2003; 40 (2 Suppl 3): 83–91.
  Article CAS PubMed Google Scholar
• Danhauser-Riedl S, Warmuth M, Druker BJ, Emmerich B, Hallek M . Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res 1996; 56: 3589–3596.
  CAS PubMed Google Scholar
• Plattner R, Kadlec L, DeMali KA, Kazlauskas A, Pendergast AM . c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev 1999; 13: 2400–2411.
  Article CAS PubMed PubMed Central Google Scholar
• Warmuth M, Forster K, Stanglmaier M, Schuster C, Hallek M . PP1, a tyrosine kinase inhibitor specific for Src-family kinases, selectively inhibits survival of BCR-ABL expressing myeloid cells. Blood 1999; 94 (Suppl.1): 387a.
  Google Scholar
• Lionberger JM, Wilson MB, Smithgall TE . Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J Biol Chem 2000; 275: 18581–18585.
  Article CAS PubMed Google Scholar
• Clarkson B, Strife A, Wisniewski D, Lambek CL, Liu C . Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. Leukemia 2003; 17: 1211–1262.
  Article CAS PubMed Google Scholar
• Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003; 63: 375–381.
  CAS PubMed Google Scholar
• La Rosee P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ . Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res 2002; 62: 7149–7153.
  CAS PubMed Google Scholar
• Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002; 62: 4236–4243.
  CAS PubMed Google Scholar
• Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J . Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 2000; 289: 1938–1942.
  Article CAS PubMed Google Scholar
• Azam M, Latek RR, Daley GQ . Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003; 112: 831–843.
  Article CAS PubMed Google Scholar
• Ihle JN, Keller J, Henderson L, Klein F, Palaszynski E . Procedures for the purification of interleukin 3 to homogeneity. J Immunol 1982; 129: 2431–2436.
  CAS PubMed Google Scholar
• Kabarowski JH, Allen PB, Wiedemann LM . A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells. EMBO J 1994; 13: 5887–5895.
  Article CAS PubMed PubMed Central Google Scholar
• Hoover RR, Mahon FX, Melo JV, Daley GQ . Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 2002; 100: 1068–1071.
  Article CAS PubMed Google Scholar
• von Bubnoff N, Veach DR, Miller WT, Li W, Sanger J, Peschel C et al. Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors. Cancer Res 2003; 63: 6395–6404.
  CAS PubMed Google Scholar
• Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, Moasser MM . A Novel pyridopyrimidine inhibitor of Abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin Cancer Res 2003; 9: 1267–1273.
  CAS PubMed Google Scholar
• Melo JV, Hughes TP, Apperley JF . Chronic myeloid leukemia. Hematology (Am Soc Hematol Educ Program) 2003, 132–152.
• Hochhaus A . Cytogenetic and molecular mechanisms of resistance to imatinib. Semin Hematol 2003; 40 (2 Suppl 3): 69–79.
  Article CAS PubMed Google Scholar
• Dorsey JF, Jove R, Kraker AJ, Wu J . The pyrido[2,3-_d_]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res 2000; 60: 3127–3131.
  CAS PubMed Google Scholar
• Wisniewski D, Lambek CL, Liu C, Strife A, Veach DR, Nagar B et al. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res 2002; 62: 4244–4255.
  CAS PubMed Google Scholar